HOOKIPA Pharma
HOOK
HOOK was delisted on the 7th of August, 2025.
36 hedge funds and large institutions have $88.7M invested in HOOKIPA Pharma in 2019 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 21 increasing their positions, 5 reducing their positions, and 2 closing their positions.
320% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 5
79% more capital invested
Capital invested by funds: $49.7M → $88.7M (+$39M)
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
3% more funds holding
Funds holding: 35 → 36 (+1)
0.29% more ownership
Funds ownership: 3.07% → 3.36% (+0.29%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.66M |
| 2 |
BlackRock
New York
|
+$2.48M |
| 3 |
State Street
Boston,
Massachusetts
|
+$581K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$421K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$346K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$1.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$914K |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$44.2K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$8.58K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$8K |
HOOK Hedge Fund Activity: Q4 2019 in Review
36 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in HOOKIPA Pharma (HOOK) for Q4 2019, worth a combined $88.7M — up 79% from $49.7M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new HOOK positions and 2 closed out — a net gain of 1 holder — while 21 added to existing stakes and 5 trimmed.
The largest buyer was Vanguard Group, adding an estimated $2.66M. The largest seller was Artal Group, cutting an estimated $1.1M.
- 36 institutional investors held HOOKIPA Pharma (HOOK) as of Q4 2019, up from 35 in Q3 2019.
- Funds reported $88.7M of HOOKIPA Pharma stock for Q4 2019, up 79% quarter-over-quarter.
- 3 funds opened new HOOKIPA Pharma positions in Q4 2019 and 2 closed out, a net change of +1 holder.
- The largest HOOKIPA Pharma buyer in Q4 2019 was Vanguard Group, an estimated $2.66M added.
- The largest HOOKIPA Pharma seller in Q4 2019 was Artal Group, an estimated $1.1M sold.
Based on aggregated 13F filings for Q4 2019.